Melan-A/MART-1-specific CD8 T cells: From thymus to tumor

Trends in Immunology

Volumn 23, Issue 7, 2002, Pages 325-328

  Pittet, Mikaël J ^a   Zippelius, Alfred ^a   Valmori, Danila ^a   Speiser, Daniel E ^a   Cerottini, Jean Charles ^a   Romero, Pedro ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A2 ANTIGEN; MELAN A; TETRAMER;

CANCER; CANCER PATIENT; HUMAN; MELANOMA; REVIEW; T LYMPHOCYTE; THYMUS; VACCINATION;

ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; MELANOMA; NEOPLASM PROTEINS; THYMUS GLAND;

EID: 0036644737     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02244-5     Document Type: Review

References (27)

1. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
2. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
3. Subcellular localization of the melanoma-associated protein Melan-A/MART-1 influences the processing of its HLA-A2-restricted epitope
4. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
5. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
7. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
8. High frequencies of naïve Melan-A/MART-1-specific CD8? T cells in a large proportion of HLA-A2 individuals
9. A shift in the phenotype of Melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
10. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
11. Peptides derived from self-proteins as partial agonists and antagonists of human CD8? T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
12. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells
13. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
14. Thymic selection generates a large T cell pool recognizing a self-peptide in humans
15. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self
16. Changes in thymic function with age and during the treatment of HIV infection
17. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex-peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo
18. HLA-A2 restricted, melanocyte-specific CD8? T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1
19. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
20. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A
21. In vivo activation of melanoma specific CD8 T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells
22. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
23. Immune and clinical responses in patients with metastatic melanoma to CD34? progenitor-derived dendritic cell vaccine
24. Vaccination with a Melan-A peptide selects an oligoclonal T-cell population with increased functional avidity and tumor reactivity
25. Crystal structures of two closely related but antigenically distinct HLA-A2-melanocyte-melanoma tumor-antigen peptide complexes
26. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
27. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice